Supplementary Material for: Impact of Renal Disease on Patients with Hepatitis C: A Retrospective Analysis of Disease Burden, Clinical Outcomes, and Health Care Utilization and Cost

Background/Aims: Few studies explore the magnitude of
the disease burden and health care utilization imposed by renal disease
among patients with hepatitis C virus (HCV). We aimed to describe the
characteristics, outcomes, and health care utilization and costs of
patients with HCV with and without renal impairment. Methods:
This retrospective analysis used 2 administrative claims databases: the
US commercially insured population in Truven Health MarketScan® data
(aged 20-64 years), and the US Medicare fee-for-service population in
the Medicare 20% sample (aged ≥65 years). Baseline characteristics and
comorbid conditions were identified from claims during 2011; patients
were followed for up to 1 year (beginning January 1, 2012) to identify
health outcomes of interest and health care utilization and costs. Results:
In the MarketScan and Medicare databases, 35,965 and 10,608 patients
with HCV were identified, 8.5 and 26.5% with evidence of renal disease
(chronic kidney disease [CKD] or end-stage renal disease [ESRD]). Most
comorbid conditions and unadjusted outcome rates increased across groups
from patients with no evidence of renal disease to non-ESRD CKD to
ESRD. Health care utilization followed a similar pattern, as did the
costs. Conclusions: Our findings suggest that HCV patients
with concurrent renal disease have significantly more comorbidity, a
higher likelihood of negative health outcomes, and higher health care
utilization and costs.